International Conference on “Recent trends in Pharmacovigilance and Drug Safety” (RTPD-2022)

Journal of Medical Pharmaceutical and allied Sciences

Conference dates April 29th – 30th , 2022

About Uttaranchal University

Uttaranchal University was established vide Uttaranchal University Act 2012 passed by the Legislative Assembly, Uttarakhand Government [Uttarakhand Act No.11 of 2013]. Uttaranchal University is duly recognized by University Grants Commission [UGC], India’s highest regulatory body for higher education, under section 2(f) of UGC Act 1956. Uttaranchal University Degrees and Diplomas are conferred as per the provisions of Section 22, of UGC Act 1956.
The Uttaranchal University offers a unique life to its students and a vibrant campus life. They get access to comprehensive facilities, cultural activities, wide range of academic programmes and industry interface.

Chief Patron

Sh. Jitender Joshi
Chancellor, Uttaranchal University


Prof.(Dr.) Dharam Buddhi
Vice Chancellor, Uttaranchal University


Prof. (Dr.) Rajesh Bahuguna
Pro Vice Chancellor, Uttaranchal University


Pharmacovigilance and Drug Safety Conference aims to bring together leading academic scientists, researchers and research scholars to exchange and share their experiences and research results on all aspects of these subjects. It also provides a premier interdisciplinary platform for researchers, practitioners, and educators to present and discuss the most recent innovations, trends, and concerns as well as practical challenges encountered and solutions adopted in the fields of Pharmacovigilance, Drug safety and Clinical Research.

Pharmacovigilance and Drug Safety comprises set of pharmacovigilance activities and interventions designed to identify, characterize, prevent or minimize risks relating to medicinal and therapeutic products including the assessment of the effectiveness of their clinical interventions and combination therapies. Drug industry need to promote companies in pharmacovigilance practice to use information technology and to review software used in pharmacovigilance and clinical trials. Monitoring unlicensed, off labels and orphan drugs is major task in risk management. Many experts from different pharmacovigilance CRO's, pharmacovigilance service providers and industrial delegates are participating in this conference to share their knowledge and discuss about the new updates.

Clinical trials allow the drug to be tested for safety by different ethnic population. Due to the higher medical needs and increasing disease prevalence, developing countries are becoming a hub for clinical trial execution. There are numerous clinical trials started by scholarly clinical scientists. Whether started by industry or by scholastic clinical examiners and research is frequently performed in national, European and overall consortia, which can be expansive ones. Clinical research brings up moral and security issues. Clinical research is exceedingly controlled. To encourage and coordinated efforts crosswise over fringes.

Adverse drug reactions can be considered a form of toxicity or enhanced drug effects that occur during appropriate use (e.g., when drug metabolism is temporarily inhibited by a disorder or another drug). ADRs occur during 10 to 20% of hospitalizations; about 10 to 20% of these ADRs are severe. Incidence of death due to ADRs is unknown; suggested rates of 0.5 to 0.9% may be falsely high because many of the patients included had serious and complex disorders. Incidence and severity of adverse drug reactions vary by patient characteristics (e.g., age, sex, ethnicity, coexisting disorders, genetic or geographic factors) and by drug factors (e.g., type of drug, administration route, treatment duration, dosage, and bioavailability). Incidence is higher with advanced age and polypharmacy.

This conference will provide opportunities for Research Scholars, Educators, Industry Professionals, Practitioners to exchange new ideas and application experiences and cover the articles from diversified field of Pharmacovigilance, Clinical Research, Regulatory Affairs, Pharmacology and Toxicology and Novel Drug Delivery System, Food Technology and Nutraceuticals, Nanotechnology, Biopharmaceutics and Pharmacokinetics, Pharmacoepidemiology, Pharmacoeconomics, Pharmaceutical Microbiology, Biochemistry, Biotechnology and other allied sciences.